TapewireFind a company

person · Reporting owner

O'Kane Kieran

Disclosed activity across 1 company

Tapewire entity
65172
SEC CIK
0001828131

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIODESIX INCBDSX · Entity 6053Chief Commercial OfficerFebruary 20, 2026February 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIODESIX INC

Report date February 20, 2026 · Filed February 24, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect9,819 Ending reported balance After 2026-02-23 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-02-20 · Exercise / conversion · Acquired 1,469 · Balance 10,354

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Row 2 · 2026-02-23 · Sale · Disposed 535 · Balance 9,819

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect4,406 Reported balance After 2026-02-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-02-20 · Exercise / conversion · Disposed 1,469 · Balance 4,406

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 23, 2026 Filed Feb 24, 2026 01:22 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 535 $12.78 $6,834.95
Disclosure

SEC source: 0000905148-26-000986 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,819

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 01:22 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,469 $0.00 $0.00
Disclosure

SEC source: 0000905148-26-000986 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,406

Underlying: Common Stock · 1,469 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F4 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F4 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 01:22 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,469 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-26-000986 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,354

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
February 10, 2026 Filed Feb 11, 2026 23:03 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 584 $10.08 $5,889.11
Disclosure

SEC source: 0000905148-26-000635 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,885

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 23:03 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,527 $0.00 $0.00
Disclosure

SEC source: 0000905148-26-000635 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,526

Underlying: Common Stock · 1,527 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F6 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 23:03 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 73 $0.00 $0.00
Disclosure

SEC source: 0000905148-26-000635 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 73 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date.

F4 · derivative.expiration_date: These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date.

Read SEC document
February 09, 2026 Filed Feb 11, 2026 23:03 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,600 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-26-000635 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 16, 2026 Filed Jan 20, 2026 21:21 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 298 $8.15 $2,428.49
Disclosure

SEC source: 0000905148-26-000251 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,869

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 15, 2026 Filed Jan 20, 2026 21:21 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 805 $0.00 $0.00
Disclosure

SEC source: 0000905148-26-000251 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,609

Underlying: Common Stock · 805 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F4 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

F4 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

Read SEC document
January 15, 2026 Filed Jan 20, 2026 21:21 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 805 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-26-000251 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 21:25 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to Buy) · Derivative 27,000 $0.00 Strike: $6.46 $0.00
Disclosure

SEC source: 0000905148-26-000067 · form4.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2036-01-01

F1 · derivative.exercise_date: This option vests in a series of forty-eight successive, substantially equal monthly installments measured from January 2, 2026, generally subject to the Reporting Person's continued service through each applicable vesting date.

Read SEC document
November 10, 2025 Filed Nov 13, 2025 21:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 75 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-003931 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73

Underlying: Common Stock · 75 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F1 · derivative.underlying_shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").

F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").

Read SEC document
November 10, 2025 Filed Nov 13, 2025 21:53 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 25 $7.62 $190.50
Disclosure

SEC source: 0000905148-25-003931 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,362

F4 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

Read SEC document
November 10, 2025 Filed Nov 13, 2025 21:53 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 75 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-25-003931 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,387

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").

F2 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F1 · balance_after: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025 (the "Reverse Stock Split").

F3 · balance_after: Includes 309 shares of the Issuer's Common Stock, as adjusted for the Reverse Stock Split, purchased under the Issuer's Employee Stock Purchase Plan on September 2, 2025.

Read SEC document
August 13, 2025 Filed Aug 14, 2025 21:24 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 476 $0.42 $198.16
Disclosure

SEC source: 0000905148-25-002982 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,065

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.4076 to $0.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 12, 2025 Filed Aug 14, 2025 21:24 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-002982 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,979

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F4 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 12, 2025 Filed Aug 14, 2025 21:24 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,489 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-25-002982 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
May 13, 2025 Filed May 13, 2025 22:35 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 238 $0.35 $83.99
Disclosure

SEC source: 0000905148-25-001607 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,052

F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.3395 to $0.3622, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 12, 2025 Filed May 13, 2025 22:35 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 239 $0.36 $85.90
Disclosure

SEC source: 0000905148-25-001607 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,290

F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.3431 to $0.4014, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 09, 2025 Filed May 13, 2025 22:35 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,490 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-001607 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,468

Underlying: Common Stock · 1,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 09, 2025 Filed May 13, 2025 22:35 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,490 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-25-001607 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,529

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 10,000 shares purchased under the Issuer's Employee Stock Purchase Plan on February 28, 2025.

Read SEC document
February 20, 2025 Filed Feb 26, 2025 21:32 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 87,319 $0.00 Strike: $0.92 $0.00
Disclosure

SEC source: 0000905148-25-000780 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,319

Underlying: Common Stock · 87,319 shares

Expires 2035-02-19

F4 · derivative.exercise_date: This option vested in full on February 20, 2025. Under the Issuer's 2024 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2024 in the form of a fully-vested option.

Read SEC document
February 20, 2025 Filed Feb 26, 2025 21:32 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 235,000 $0.00 Strike: $0.92 $0.00
Disclosure

SEC source: 0000905148-25-000780 · form4.xml · derivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 235,000

Underlying: Common Stock · 235,000 shares

Expires 2035-02-19

F3 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from February 20, 2025, generally subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
February 20, 2025 Filed Feb 26, 2025 21:32 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 117,500 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-000780 · form4.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,500

Underlying: Common Stock · 117,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F2 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 11, 2025 Filed Feb 12, 2025 22:11 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 17,527 $0.92 $16,198.45
Disclosure

SEC source: 0000905148-25-000526 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,039

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $0.90 to $0.9536, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 22:11 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 16,095 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-000526 · form4.xml · derivative · entry 5

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,286

Underlying: Common Stock · 16,095 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 22:11 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 30,534 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-000526 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,067

Underlying: Common Stock · 30,534 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 22:11 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0000905148-25-000526 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,958

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F4 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F4 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 10, 2025 Filed Feb 12, 2025 22:11 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 48,118 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-25-000526 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
November 12, 2024 Filed Nov 13, 2024 21:21 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 224 $1.40 $313.78
Disclosure

SEC source: 0000905148-24-003057 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,448

F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.39 to $1.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 11, 2024 Filed Nov 13, 2024 21:21 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 238 $1.39 $331.03
Disclosure

SEC source: 0000905148-24-003057 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,672

F3 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.36 to $1.42, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 08, 2024 Filed Nov 13, 2024 21:21 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,490 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-003057 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,447

Underlying: Common Stock · 1,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
November 08, 2024 Filed Nov 13, 2024 21:21 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,490 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-24-003057 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes 6,792 shares purchased under the Issuer's Employee Stock Purchase Plan on August 30, 2024.

Read SEC document
August 12, 2024 Filed Aug 12, 2024 23:24 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 120 $1.57 $188.63
Disclosure

SEC source: 0000905148-24-002114 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,628

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.52 to $1.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 09, 2024 Filed Aug 12, 2024 23:24 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 345 $1.60 $552.35
Disclosure

SEC source: 0000905148-24-002114 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,748

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 08, 2024 Filed Aug 12, 2024 23:24 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-002114 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,937

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
August 08, 2024 Filed Aug 12, 2024 23:24 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,489 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-24-002114 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,093

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Read SEC document
May 23, 2024 Filed May 23, 2024 23:14 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionSeries A Non-Voting Convertible Preferred Stock · Derivative 327 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-001612 · form4.xml · derivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,080 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.

F1 · derivative.exercise_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.

F1 · derivative.expiration_date: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.

Read SEC document
May 23, 2024 Filed May 23, 2024 23:14 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 13,080 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-24-001612 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.

Read SEC document
May 09, 2024 Filed May 10, 2024 21:05 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 468 $1.48 $692.41
Disclosure

SEC source: 0000905148-24-001353 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,524

F4 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F5 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.43 to $1.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 08, 2024 Filed May 10, 2024 21:05 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,489 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-001353 · form4.xml · derivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,426

Underlying: Common Stock · 1,489 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F6 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F6 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
May 08, 2024 Filed May 10, 2024 21:05 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionCommon Stock 1,489 Not disclosed Not disclosed
Disclosure

SEC source: 0000905148-24-001353 · form4.xml · nonDerivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2 · balance_after: Includes an aggregate 59 shares that were inadvertently reported as being sold on February 9 and February 12, 2024 in the Form 4 filed by the Reporting Person on February 12, 2024.

F3 · balance_after: Includes 6,439 shares purchased under the Issuer's Employee Stock Purchase Plan on February 29, 2024.

Read SEC document
April 05, 2024 Filed Apr 9, 2024 23:32 UTC BIODESIX INC BDSX · Entity 6053 GrantSeries A Non-Voting Convertible Preferred Stock · Derivative 327 $46.00 $15,042.00
Disclosure

SEC source: 0000905148-24-001139 · form4.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 327

Underlying: Common Stock · 13,080 shares

Expires not disclosed

F1 · derivative.exercise_price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date.

F1 · price: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date.

F1 · derivative.exercise_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date.

F1 · derivative.expiration_date: These shares of Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") were issued to the Reporting Person under securities purchase agreements entered into with the Issuer, pursuant to which the Issuer has agreed to submit to its stockholders the approval of the conversion of the Preferred Stock into shares of Common Stock at its 2024 annual meeting of stockholders (the "Conversion Proposal"). Following such approval of the Conversion Proposal, each share of Preferred Stock will automatically convert into 40 shares of Common Stock, subject to certain limitations, including that the Reporting Person is prohibited from converting shares of Preferred Stock into shares of Common Stock if, as a result of such conversion, the Reporting Person, together with his affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. The Preferred Stock has no expiration date.

Read SEC document
February 21, 2024 Filed Feb 29, 2024 23:16 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 35,307 $0.00 Strike: $1.46 $0.00
Disclosure

SEC source: 0000905148-24-000824 · form4.xml · derivative · entry 1

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,307

Underlying: Common Stock · 35,307 shares

Expires 2034-02-20

F1 · derivative.exercise_date: This option vested in full on February 21, 2024. Under the Issuer's 2023 Bonus-to-Options Program, the Reporting Person elected to receive a portion of the annual cash bonus earned during 2023 in the form of a fully-vested option.

Read SEC document
February 12, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 5,412 $1.66 $9,009.36
Disclosure

SEC source: 0000905148-24-000585 · form4.xml · nonDerivative · entry 3

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,005

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F4 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.55 to $1.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 09, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 SaleCommon Stock 6,319 $1.92 $12,111.00
Disclosure

SEC source: 0000905148-24-000585 · form4.xml · nonDerivative · entry 2

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,417

F2 · kind: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

F3 · price: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.8191 to $2.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 30,534 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-000585 · form4.xml · derivative · entry 7

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,601

Underlying: Common Stock · 30,534 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F8 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F8 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 Exercise / conversionRestricted Stock Units · Derivative 1,490 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-000585 · form4.xml · derivative · entry 6

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,915

Underlying: Common Stock · 1,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F7 · derivative.exercise_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F7 · derivative.expiration_date: These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 GrantStock Options (Right to buy) · Derivative 128,761 $0.00 Strike: $1.99 $0.00
Disclosure

SEC source: 0000905148-24-000585 · form4.xml · derivative · entry 5

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,761

Underlying: Common Stock · 128,761 shares

Expires 2034-02-07

F6 · derivative.exercise_date: This option vests in a series of forty-eight successive equal monthly installments measured from January 15, 2024, generally subject to the Reporting Person's continuous service through each applicable vesting date.

Read SEC document
February 08, 2024 Filed Feb 13, 2024 02:45 UTC BIODESIX INC BDSX · Entity 6053 GrantRestricted Stock Units · Derivative 64,381 $0.00 $0.00
Disclosure

SEC source: 0000905148-24-000585 · form4.xml · derivative · entry 4

O'Kane Kieran · CIK 0001828131 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,381

Underlying: Common Stock · 64,381 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5 · derivative.exercise_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

F5 · derivative.expiration_date: These RSUs vest in a series of four successive equal annual installments measured from January 15, 2024, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.